Promise Bio Secures $8.3 Million for Auto-Immune Precision Drugs Platform –
What you’ll want to know:
– Promise Bio, a startup remodeling the remedy of immune-mediated ailments with superior precision medication options, in the present day introduced it has emerged from stealth with an $8.3 million seed funding.
– This funding will speed up the event of Promise Bio's computational platform, which makes use of epiproteomics and synthetic intelligence to foretell affected person remedy responses and assist drug analysis and growth.
Revolutionizing the administration of immune-mediated ailments by means of epiproteomics and AI
Promise Bio is a pioneer in precision medication, advancing the administration of immune-mediated ailments with an progressive deal with epiproteomics and synthetic intelligence (AI). Leveraging cutting-edge analysis from the Weizmann Institute of Science, the corporate's proprietary know-how allows large-scale profiling of post-translational modifications (PTMs) in proteins. This platform identifies illness mechanisms, tailors therapies and discovers new drug targets with unparalleled precision.
On the coronary heart of Promise Bio's success is its proprietary PROMISE platform (Protein Modification Built-in Search Engine), developed by co-founder and CTO Dr. Assaf Kacen. This groundbreaking system, based mostly on elementary analysis performed within the laboratory of Prof. Yifat Merbl on the Weizmann Institute and revealed in Nature Biotechnology will allow high-throughput profiling of dozens of PTMs utilizing mass spectrometry in 2023. The platform eliminates the necessity for customized chemical enrichment or extra laboratory procedures, considerably streamlining the evaluation of PTMs and accelerating biomedical discovery.
Strategic partnerships with two main biopharmaceutical corporations improve Promise Bio's potential to combine its know-how into international drug growth pipelines. These alliances provide:
- Monetary assistthus making certain sustainable innovation.
- Business experienceenabling efficient translation of analysis into scientific purposes.
- Entry to international networksfostering collaboration and increasing the attain of precision medication options.
By constructing the world's largest PTM database, Promise Bio is creating an indispensable useful resource for medical breakthroughs whereas addressing urgent scientific challenges in immune-mediated ailments.
Addressing the unmet want for precision remedies, Promise Bio addresses the present inefficiencies in therapies for autoimmune ailments, with solely 30-40% of sufferers reaching vital remission. The corporate emphasizes data-driven approaches to eradicate the trial-and-error remedy paradigm. The PROMISE platform focuses not solely on protein ranges, but in addition on the modifications that proteins endure after formation, offering actionable insights for tailor-made interventions.
“Proteins are the constructing blocks of the human physique, and understanding the modifications after their formation is essential to fixing the challenges of immune-mediated ailments,” explains Ronel Veksler, co-founder and CEO. With this imaginative and prescient, Promise Bio is poised to remodel the way forward for precision medication.